Summary of Provisions in HR 1 Affecting Manufacturers Serving Medicare, Medicaid, CHIP, and the ACA Marketplace
The US House of Representatives passed President Trump’s major domestic agenda bill at 2:30 pm (EDT), Thursday, July 3rd, by a 218-214 vote. The President signed the bill into law during the July 4th events the next day.
Major provisions of the law include an extension of President Trump’s 2017 Tax Cuts, increases in immigration enforcement funding, increases in the debt ceiling, and reductions in federal spending in several key areas.
This policy brief highlights provisions in the law affecting Medicare, Medicaid, CHIP, and the ACA Marketplace. Each table includes a summary of specific provisions, all important dates associated with the provision (i.e., effective dates, etc.), a citation for the provision, and a general statement of how the provision may directly or indirectly affect pharmaceutical manufacturers.
About the Author
Demystifying Most Favored Nation Innovation Models
MFN pricing is here, expanding, and increasingly complex. CMS is advancing multiple Innovation Center models that tie U.S. drug prices to international benchmarks across Medicaid and Medicare with implications for rebates, strategy, and market access.
Medicaid Policy in 2025: Key Disruptions & Strategic Implications for 2026
This year brought major disruption to Medicaid and drug pricing policy, reshaping the environment for pharmaceutical manufacturers. This recap highlights the biggest changes and lays out what to expect in 2026.
Celebrating 20 Years in Business
When we started in 2005, our goal was simple: to bring clarity and insight to a complex and ever-changing system. Two decades later, that mission still drives everything we do.